Register Login
Register to leave comments
  • News bot Aug. 3, 2026, 8:20 p.m.

    📋 ORIC PHARMACEUTICALS, INC. (ORIC) - Financial Results

    Filing Date: 2026-08-03

    Accepted: 2026-08-03 16:10:16

    Event Type: Financial Results

    Event Details:

    ORIC PHARMACEUTICALS, INC. (ORIC) Reports the reporting period Financial Results ORIC PHARMACEUTICALS, INC. (ORIC) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 264761
      • targeting EGFR exon 20 insertion mutations and EGFR atypical mutationsEnozertinib is currently being evaluated in Phase 1b trials across the following first-line patient populations with advanced NSCLC:•As a single-agent in patients with EGFR atypical mutations.•As a single-agent in patients with EGFR exon 20 insertion mutations.•In combination with subcutaneous (SC) amivantamab and in combination with chemotherapy in patients with EGFR exon 20 insertion mutations. Anticipated Program Milestones: ORIC anticipates the following upcoming milestones:•Rinzimetostat in mCRPC: −2H 2026
      • targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 8.93K 6.98K $1.96K +28.03%
    Current Assets Property Equipment Net 2.24K 2.42K $-173.00 -7.16%
    Current Assets Other Assets 5.95K 7.25K $-1.30K -17.91%
    Current Liabilities Accounts Payable 3.87K 3.82K $49.00 +1.28%
    Current Liabilities Accrued Liabilities 16.88K 16.59K $290.00 +1.75%
    Current Liabilities Other Long Term Liabilities 2.67K 4.11K $-1.44K -34.98%
    Operating Expenses Loss From Operations 39.06K 84.92K $-45.85K -54.00%
    Operating Expenses Other Income Net 2.71K 7.66K $-4.95K -64.62%
    Operating Expenses Net Loss 36.35K 77.26K $-40.90K -52.94%
    Other Comprehensive Loss Net Loss Per Share 0.47 0.72 $-0.25 -34.72%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ORIC PHARMACEUTICALS, INC.
    • Ticker Symbol: ORIC

Search

News categories